• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PXS
Click for more information
0.00% 8.5¢

PHARMAXIS LTD - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
PXSTrading HaltPRICE SENSITIVE22/04/13
PXSAppendix 4C - quarterlyPRICE SENSITIVE10/04/13
PXSPHARMAXIS RECEIVES COMPLETE RESPONSE LETTER FROM FDAPRICE SENSITIVE19/03/13
PXSTrading HaltPRICE SENSITIVE19/03/13
PXSPharmaxis Appoints Gary Phillips New Chief Executive OfficerPRICE SENSITIVE12/03/13
PXSBronchiectasis Phase 3 Trial MilestonePRICE SENSITIVE08/03/13
PXSHalf Year Report and AccountsPRICE SENSITIVE15/02/13
PXSPharmaxis Announces US$40 million Financing AreementPRICE SENSITIVE31/01/13
PXSPharmaxis Receives Negative Recommendation from PADACPRICE SENSITIVE31/01/13
PXSTrading HaltPRICE SENSITIVE29/01/13
PXSAppendix 4C - quarterlyPRICE SENSITIVE23/01/13
PXSIMPORTANT MILESTONE BRONCHITOL APPROVED BY NICE IN UKPRICE SENSITIVE26/10/12
PXSTrading HaltPRICE SENSITIVE26/10/12
PXSAppendix 4C - quarterlyPRICE SENSITIVE10/10/12
PXSResponse to ASX Price QueryPRICE SENSITIVE08/10/12
PXSPharmaxis Receives Maximum Extension to German PatentPRICE SENSITIVE27/09/12
PXSPreliminary Final ReportPRICE SENSITIVE10/08/12
PXSUS FDA Accepts Bronchitol New Drug Application for ReviewPRICE SENSITIVE02/08/12
PXSAppendix 4C - quarterlyPRICE SENSITIVE17/07/12
PXSAdditional Data Bronchitol Reduces Risk of ExacerbationsPRICE SENSITIVE08/06/12
PXSBronchitol Commercial Progress in EuropePRICE SENSITIVE01/06/12
PXSPharmaxis Submits US New Drug Application for BronchitolPRICE SENSITIVE21/05/12
PXSPharmaxis Receives Approval to Market Bronchitol in the EUPRICE SENSITIVE20/04/12
PXSAppendix 4C - quarterlyPRICE SENSITIVE18/04/12
PXSPXS Completes Phase II study with ASM8 in asthma patientsPRICE SENSITIVE17/04/12
PXSPharmaxis Announces Agreement for EU Supply of BronchitolPRICE SENSITIVE29/03/12
PXSEuropean Regulatiry Update on BronchitolPRICE SENSITIVE16/03/12
PXSBronchitol to be Reimbursed in AustraliaPRICE SENSITIVE14/03/12
PXSHalf Yearly Report and AccountsPRICE SENSITIVE03/02/12
PXSAppendix 4C - quarterlyPRICE SENSITIVE24/01/12
PXSPharmaxis Files PBAC Minor Resubmission for BronchitolPRICE SENSITIVE20/12/11
PXSPhase 3 Trial in Bronchiectasis Reaches Recruitment TargetPRICE SENSITIVE13/12/11
PXSRetail Offer BookletPRICE SENSITIVE24/11/11
PXSInstitutional Component of Entitlement OfferPRICE SENSITIVE18/11/11
PXSTrading HaltPRICE SENSITIVE16/11/11
PXSPharmaxis Announces PBAC Decision on BronchitolPRICE SENSITIVE09/11/11
PXSReinstatement to Official QuotationPRICE SENSITIVE24/10/11
PXSPharmaxis Announces Positive Bronchitol Opinion for EuropePRICE SENSITIVE24/10/11
PXSSuspension from Official QuotationPRICE SENSITIVE20/10/11
PXSTrading HaltPRICE SENSITIVE17/10/11
PXSAppendix 4C - quarterlyPRICE SENSITIVE12/10/11
PXSPhase II Trial in Allergic Asthma Completes RecruitmentPRICE SENSITIVE29/09/11
PXSUpdate on EU Bronchitol Marketing ApplicationPRICE SENSITIVE28/09/11
PXSRe-examination Documents Filed for EU Bronchitol ApplicationPRICE SENSITIVE22/08/11
PXSPreliminary Final ReportPRICE SENSITIVE12/08/11
PXSAppendix 4C - quarterlyPRICE SENSITIVE20/07/11
PXSBronchitol Resubmitted to Australian PBACPRICE SENSITIVE12/07/11
PXSRe-examination of Bronchitol Marketing Application RequestedPRICE SENSITIVE05/07/11
PXSEU Marketing Authorisation Application Review of BronchitolPRICE SENSITIVE27/06/11
PXSEU CHMP Confirms Negative Trend Vote on BronchitolPRICE SENSITIVE24/06/11
PXSResponse to ASX Query LetterPRICE SENSITIVE31/05/11
PXSPharmaxis Receives Negative Bronchitol Trend Vote from CHMPPRICE SENSITIVE25/05/11
PXSTrading HaltPRICE SENSITIVE23/05/11
PXSBronchitol Deferred by Australian PBACPRICE SENSITIVE21/04/11
PXSAppendix 4C - quarterlyPRICE SENSITIVE13/04/11
PXSAustralian TGA Approves Bronchitol for Cystic FibrosisPRICE SENSITIVE08/02/11
PXSHalf Yearly Report and AccountsPRICE SENSITIVE04/02/11
PXSAppendix 4C - quarterlyPRICE SENSITIVE25/01/11
PXSEU Bronchitol Marketing Application UpdatePRICE SENSITIVE25/01/11
PXSBronchitol EU Marketing Authorisation UpdatePRICE SENSITIVE20/12/10
PXSExtended Benefit with Bronchitol in Second PhaseIII CF TrialPRICE SENSITIVE16/12/10
PXSBronchitol Recommended for Approval by Australian Advisory CPRICE SENSITIVE13/12/10
PXSPhase II Trial of ASM8 in Asthma CommencesPRICE SENSITIVE07/12/10
PXSPharmaxis Announces Positive Combined Phase 3 CF ResultsPRICE SENSITIVE22/10/10
PXSAppendix 4C - quarterlyPRICE SENSITIVE13/10/10
PXSUS FDA APPROVES ARIDOLPRICE SENSITIVE06/10/10
PXSAgreement for European Marketing of BronchitolPRICE SENSITIVE31/08/10
PXSAppendix 4C - quarterlyPRICE SENSITIVE21/07/10
PXSResults for Second Phase 3 Trial of Bronchitol in CFPRICE SENSITIVE22/06/10
PXSTrading HaltPRICE SENSITIVE21/06/10
PXSSustained Benefit Following 18 Month Bronchitol TreatmentPRICE SENSITIVE17/05/10
PXSAppendix 4C - quarterly March 2010PRICE SENSITIVE14/04/10
PXSPharmaxis Announces Milestone in Phase 3 Trial for CFPRICE SENSITIVE14/04/10
PXSPharmaxis Completes Phase II Clinical Study with ASM8PRICE SENSITIVE11/03/10
PXSPharmaxis completes clinical trial with PXS25PRICE SENSITIVE09/02/10
PXSHalf Yearly Report and AccountsPRICE SENSITIVE05/02/10
PXSAppendix 4C - Quarterly Cash FlowPRICE SENSITIVE27/01/10
PXSPharmaxis to acquire Canadian company TOPIGEN PharmaceuticalPRICE SENSITIVE12/01/10
PXSPharmaxis receives response letter from the FDA on AridolPRICE SENSITIVE29/12/09
PXSPharmaxis lodges TGA application to market Bronchitol for CFPRICE SENSITIVE17/12/09
PXSPHARMAXIS ANNOUNCES SUSTAINED BENEFIT WITH BRONCHITOLPRICE SENSITIVE02/12/09
PXSPharmaxis Applies to Market Bronchitol for CF in EuropePRICE SENSITIVE29/10/09
PXSCommencement of Bronchiectasis Study and Aligning StrategyPRICE SENSITIVE23/10/09
PXSAppendix 4C - quarterlyPRICE SENSITIVE14/10/09
PXSSecond CF Trial Passes Recruitment TargetPRICE SENSITIVE18/09/09
PXSPreliminary Final ReportPRICE SENSITIVE14/08/09
PXSAppendix 4C - Quarterly Cash FlowPRICE SENSITIVE22/07/09
PXSPhase 3 CF Trial Results Presented at European ConferencePRICE SENSITIVE16/06/09
PXSPharmaxis Announces Placement of $47 Million and SPPPRICE SENSITIVE04/06/09
PXSTrading HaltPRICE SENSITIVE02/06/09
PXSUS FDA Accepts Aridol New Drug Application for ReviewPRICE SENSITIVE14/05/09
PXSPharmaxis Announces Positive Results of Phase 3 CF TrialPRICE SENSITIVE04/05/09
PXSTrading HaltPRICE SENSITIVE04/05/09
PXSAppendix 4C - quarterlyPRICE SENSITIVE08/04/09
PXSPharmaxis Announces Milestone in Phase III Trial for CFPRICE SENSITIVE01/04/09
PXSPharmaxis Appoints French Distributor for AridolPRICE SENSITIVE11/03/09
PXSAridol New Drug Application Submitted to FDAPRICE SENSITIVE02/03/09
PXSHalf Yearly Report - December 2008PRICE SENSITIVE06/02/09
PXSAppendix 4C - quarterlyPRICE SENSITIVE28/01/09
PXSTrading Halt
22/04/13PRICE SENSITIVE
PXSAppendix 4C - quarterly
10/04/13PRICE SENSITIVE
PXSPHARMAXIS RECEIVES COMPLETE RESPONSE LETTER FROM FDA
19/03/13PRICE SENSITIVE
PXSTrading Halt
19/03/13PRICE SENSITIVE
PXSPharmaxis Appoints Gary Phillips New Chief Executive Officer
12/03/13PRICE SENSITIVE
PXSBronchiectasis Phase 3 Trial Milestone
08/03/13PRICE SENSITIVE
PXSHalf Year Report and Accounts
15/02/13PRICE SENSITIVE
PXSPharmaxis Announces US$40 million Financing Areement
31/01/13PRICE SENSITIVE
PXSPharmaxis Receives Negative Recommendation from PADAC
31/01/13PRICE SENSITIVE
PXSTrading Halt
29/01/13PRICE SENSITIVE
PXSAppendix 4C - quarterly
23/01/13PRICE SENSITIVE
PXSIMPORTANT MILESTONE BRONCHITOL APPROVED BY NICE IN UK
26/10/12PRICE SENSITIVE
PXSTrading Halt
26/10/12PRICE SENSITIVE
PXSAppendix 4C - quarterly
10/10/12PRICE SENSITIVE
PXSResponse to ASX Price Query
08/10/12PRICE SENSITIVE
PXSPharmaxis Receives Maximum Extension to German Patent
27/09/12PRICE SENSITIVE
PXSPreliminary Final Report
10/08/12PRICE SENSITIVE
PXSUS FDA Accepts Bronchitol New Drug Application for Review
02/08/12PRICE SENSITIVE
PXSAppendix 4C - quarterly
17/07/12PRICE SENSITIVE
PXSAdditional Data Bronchitol Reduces Risk of Exacerbations
08/06/12PRICE SENSITIVE
PXSBronchitol Commercial Progress in Europe
01/06/12PRICE SENSITIVE
PXSPharmaxis Submits US New Drug Application for Bronchitol
21/05/12PRICE SENSITIVE
PXSPharmaxis Receives Approval to Market Bronchitol in the EU
20/04/12PRICE SENSITIVE
PXSAppendix 4C - quarterly
18/04/12PRICE SENSITIVE
PXSPXS Completes Phase II study with ASM8 in asthma patients
17/04/12PRICE SENSITIVE
PXSPharmaxis Announces Agreement for EU Supply of Bronchitol
29/03/12PRICE SENSITIVE
PXSEuropean Regulatiry Update on Bronchitol
16/03/12PRICE SENSITIVE
PXSBronchitol to be Reimbursed in Australia
14/03/12PRICE SENSITIVE
PXSHalf Yearly Report and Accounts
03/02/12PRICE SENSITIVE
PXSAppendix 4C - quarterly
24/01/12PRICE SENSITIVE
PXSPharmaxis Files PBAC Minor Resubmission for Bronchitol
20/12/11PRICE SENSITIVE
PXSPhase 3 Trial in Bronchiectasis Reaches Recruitment Target
13/12/11PRICE SENSITIVE
PXSRetail Offer Booklet
24/11/11PRICE SENSITIVE
PXSInstitutional Component of Entitlement Offer
18/11/11PRICE SENSITIVE
PXSTrading Halt
16/11/11PRICE SENSITIVE
PXSPharmaxis Announces PBAC Decision on Bronchitol
09/11/11PRICE SENSITIVE
PXSReinstatement to Official Quotation
24/10/11PRICE SENSITIVE
PXSPharmaxis Announces Positive Bronchitol Opinion for Europe
24/10/11PRICE SENSITIVE
PXSSuspension from Official Quotation
20/10/11PRICE SENSITIVE
PXSTrading Halt
17/10/11PRICE SENSITIVE
PXSAppendix 4C - quarterly
12/10/11PRICE SENSITIVE
PXSPhase II Trial in Allergic Asthma Completes Recruitment
29/09/11PRICE SENSITIVE
PXSUpdate on EU Bronchitol Marketing Application
28/09/11PRICE SENSITIVE
PXSRe-examination Documents Filed for EU Bronchitol Application
22/08/11PRICE SENSITIVE
PXSPreliminary Final Report
12/08/11PRICE SENSITIVE
PXSAppendix 4C - quarterly
20/07/11PRICE SENSITIVE
PXSBronchitol Resubmitted to Australian PBAC
12/07/11PRICE SENSITIVE
PXSRe-examination of Bronchitol Marketing Application Requested
05/07/11PRICE SENSITIVE
PXSEU Marketing Authorisation Application Review of Bronchitol
27/06/11PRICE SENSITIVE
PXSEU CHMP Confirms Negative Trend Vote on Bronchitol
24/06/11PRICE SENSITIVE
PXSResponse to ASX Query Letter
31/05/11PRICE SENSITIVE
PXSPharmaxis Receives Negative Bronchitol Trend Vote from CHMP
25/05/11PRICE SENSITIVE
PXSTrading Halt
23/05/11PRICE SENSITIVE
PXSBronchitol Deferred by Australian PBAC
21/04/11PRICE SENSITIVE
PXSAppendix 4C - quarterly
13/04/11PRICE SENSITIVE
PXSAustralian TGA Approves Bronchitol for Cystic Fibrosis
08/02/11PRICE SENSITIVE
PXSHalf Yearly Report and Accounts
04/02/11PRICE SENSITIVE
PXSAppendix 4C - quarterly
25/01/11PRICE SENSITIVE
PXSEU Bronchitol Marketing Application Update
25/01/11PRICE SENSITIVE
PXSBronchitol EU Marketing Authorisation Update
20/12/10PRICE SENSITIVE
PXSExtended Benefit with Bronchitol in Second PhaseIII CF Trial
16/12/10PRICE SENSITIVE
PXSBronchitol Recommended for Approval by Australian Advisory C
13/12/10PRICE SENSITIVE
PXSPhase II Trial of ASM8 in Asthma Commences
07/12/10PRICE SENSITIVE
PXSPharmaxis Announces Positive Combined Phase 3 CF Results
22/10/10PRICE SENSITIVE
PXSAppendix 4C - quarterly
13/10/10PRICE SENSITIVE
PXSUS FDA APPROVES ARIDOL
06/10/10PRICE SENSITIVE
PXSAgreement for European Marketing of Bronchitol
31/08/10PRICE SENSITIVE
PXSAppendix 4C - quarterly
21/07/10PRICE SENSITIVE
PXSResults for Second Phase 3 Trial of Bronchitol in CF
22/06/10PRICE SENSITIVE
PXSTrading Halt
21/06/10PRICE SENSITIVE
PXSSustained Benefit Following 18 Month Bronchitol Treatment
17/05/10PRICE SENSITIVE
PXSAppendix 4C - quarterly March 2010
14/04/10PRICE SENSITIVE
PXSPharmaxis Announces Milestone in Phase 3 Trial for CF
14/04/10PRICE SENSITIVE
PXSPharmaxis Completes Phase II Clinical Study with ASM8
11/03/10PRICE SENSITIVE
PXSPharmaxis completes clinical trial with PXS25
09/02/10PRICE SENSITIVE
PXSHalf Yearly Report and Accounts
05/02/10PRICE SENSITIVE
PXSAppendix 4C - Quarterly Cash Flow
27/01/10PRICE SENSITIVE
PXSPharmaxis to acquire Canadian company TOPIGEN Pharmaceutical
12/01/10PRICE SENSITIVE
PXSPharmaxis receives response letter from the FDA on Aridol
29/12/09PRICE SENSITIVE
PXSPharmaxis lodges TGA application to market Bronchitol for CF
17/12/09PRICE SENSITIVE
PXSPHARMAXIS ANNOUNCES SUSTAINED BENEFIT WITH BRONCHITOL
02/12/09PRICE SENSITIVE
PXSPharmaxis Applies to Market Bronchitol for CF in Europe
29/10/09PRICE SENSITIVE
PXSCommencement of Bronchiectasis Study and Aligning Strategy
23/10/09PRICE SENSITIVE
PXSAppendix 4C - quarterly
14/10/09PRICE SENSITIVE
PXSSecond CF Trial Passes Recruitment Target
18/09/09PRICE SENSITIVE
PXSPreliminary Final Report
14/08/09PRICE SENSITIVE
PXSAppendix 4C - Quarterly Cash Flow
22/07/09PRICE SENSITIVE
PXSPhase 3 CF Trial Results Presented at European Conference
16/06/09PRICE SENSITIVE
PXSPharmaxis Announces Placement of $47 Million and SPP
04/06/09PRICE SENSITIVE
PXSTrading Halt
02/06/09PRICE SENSITIVE
PXSUS FDA Accepts Aridol New Drug Application for Review
14/05/09PRICE SENSITIVE
PXSPharmaxis Announces Positive Results of Phase 3 CF Trial
04/05/09PRICE SENSITIVE
PXSTrading Halt
04/05/09PRICE SENSITIVE
PXSAppendix 4C - quarterly
08/04/09PRICE SENSITIVE
PXSPharmaxis Announces Milestone in Phase III Trial for CF
01/04/09PRICE SENSITIVE
PXSPharmaxis Appoints French Distributor for Aridol
11/03/09PRICE SENSITIVE
PXSAridol New Drug Application Submitted to FDA
02/03/09PRICE SENSITIVE
PXSHalf Yearly Report - December 2008
06/02/09PRICE SENSITIVE
PXSAppendix 4C - quarterly
28/01/09PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Parkes Au-Cu project to 'transform' Adavale Resources with key targets Adavale Resources Ltd has entered into an all-scrip acquisition of the Parkes gold and copper project in New South Wales
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.